'The music stopped': Biotech rout leaves drug startups grounded as demand slumps for IPOs
Bio Pharma Dive
FEBRUARY 6, 2022
For the first time in years, biotechs no longer have an easy path onto Wall Street, a market reversal that could change what the next generation of young drugmakers looks like.
Let's personalize your content